Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Peterson

Thoracic Surgery (Cardiothoracic Vascular Surgery) Louisville, KY Medical Doctor

NPI 1265454490 CMS profile 147601

3 Audubon Plaza Dr Ste 560, Audubon Medical Plaza East, Louisville, KY 40217

Open in the dashboard

General payments

$283,098

382 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Peterson of Louisville, KY is reported in the CMS Open Payments database as having received $283,098 across 382 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,615 45
2024 General $68,873 91
2023 General $51,315 85
2022 General $68,856 64
2021 General $41,876 43
2020 General $13,714 11
2019 General $10,849 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Peterson
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Steven Peterson were reported at $27,615. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Steven Peterson Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $10,849 $886 $178–$3,167 $163
2020 $13,714 $341 $108–$1,605 $114
2021 $41,876 $453 $125–$1,886 $132
2022 $68,856 $695 $180–$2,566 $149
2023 $51,315 $745 $205–$2,662 $160
2024 $68,873 $799 $214–$2,967 $164
2025 $27,615 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Atricure, Inc. $280,970 348 payments
  2. Edwards Lifesciences Corporation $1,064 13 payments
  3. Medtronic, Inc. $314 6 payments
  4. Medtronic Vascular, Inc. $307 9 payments
  5. Abbott Laboratories $292 2 payments
  6. Baxter Healthcare $110 2 payments
  7. GlaxoSmithKline, LLC. $26 1 payment
  8. AMAG Pharmaceuticals, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $247,100 104 payments
  2. Travel and Lodging $21,451 50 payments
  3. Food and Beverage $14,532 227 payments
  4. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $216,718 191 payments
  2. ATRICLIP LAA EXCLUSION SYSTEM $64,763 76 payments
  3. SYNERGY ABLATION SYSTEM $32,550 67 payments
  4. EPI-SENSE GUIDED COAGULATION SYS $13,887 16 payments
  5. ISOLATOR SURGICAL ABLATION SYSTEM $7,650 3 payments
  6. DISSECTOR $7,650 3 payments
  7. AtriCure cryoICE cryoSPHERE Cryoablation System $6,198 13 payments
  8. LARIAT RS $1,213 1 payment
  9. ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) $1,197 9 payments
  10. ATRICURE SYNERGY ABLATION SYSTEM $1,068 11 payments
  11. Other $2,395 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

62

Median for Thoracic Surgery: 42

Drug cost

$424

Median for Thoracic Surgery: $318

Branded share of claims

0%

Median for Thoracic Surgery: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mupirocin Generic 62 $424

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 910 Part D prescribers listed as Thoracic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$135,234

Medicare's payments for the services billed

Medicare patients

130

Average age 73

Services billed

295

50 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 73%
Atrial fibrillation 65%
Heart failure 54%
Arthritis 54%
Diabetes 39%
Chronic kidney disease 38%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

382 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record